Stifel Nicolaus Issues Pessimistic Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health (NYSE:ELAN) had its target price decreased by Stifel Nicolaus from $18.00 to $16.00 in a research report sent to investors on Friday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other brokerages have also recently weighed in on ELAN. UBS Group started coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 target price for the company. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Barclays lifted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Leerink Partners started coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Finally, Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Hold” and an average target price of $16.00.

Elanco Animal Health Trading Down 1.0 %

Shares of NYSE:ELAN opened at $11.02 on Friday. The stock has a market capitalization of $5.45 billion, a price-to-earnings ratio of 27.54, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 1-year low of $10.77 and a 1-year high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company has a 50 day moving average price of $11.80 and a 200 day moving average price of $13.10.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors have recently modified their holdings of the stock. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health during the 3rd quarter valued at $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $35,000. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at $29,000. Farther Finance Advisors LLC lifted its stake in shares of Elanco Animal Health by 158.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after purchasing an additional 2,044 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its stake in shares of Elanco Animal Health by 89.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.